Recipient of the John Paul II Medal, Krakow, Poland
Researcher of the Year
The Royal Academy of Pharmacy of Spain
Xth Joan D'Alos Award, Barcelona, Spain
VIIth Internship Award
Sanofi Association for Thrombosis and Haemostasis, Florence, Italy
Dr. Hermman C.B. and Suzanne Denber Award for Excellence in Cardiovascular Research
Dr. Badimon's laboratory interests are focused in three majors aspects: 1) Role of antithrombotic agents in the genesis and treatment of acute coronary syndromes. A major line of research of our laboratory is to investigate the pathologic processes involved on the acute coronary syndromes as well as the new therapeutic possibilities. More specifically, we are studying the role of thrombin in the thrombotic process and the potential therapeutic implication of the thrombin inhibtion. Preclinical and clinical studies on the effects of direct and specific thrombin inhibitors and other inhibitors of the Tissue Factor pathway ( Inhibitors of Tissue Factor, FVIIa and/or FXa)are being studied. These studies are being carried out using a perfusion chamber originally developed in our laboratory. This device is well accepted in the literature and it is being used by several groups. We are currently involved in two clinical Phase II studies involving the antithrombotic effects of inhibitors of coagulation Factor Xa. Flow cytometry, platelet aggregation, histology and specific ELISAS are being used to investigate the mechanisms responsible for the observed antithrombotic effects 2.-Pathogenesis of Restenosis after Percutaneous Interventions.- Previous studies by our group and others have indicated a critical role for thrombosis and increased cell proliferation in the arterial response to injury and thus, in restenosis post interventions. The potential therapeutic implications of antithrombotic agents and inhibitors of the cell cycle signaling ( cdki's) are being studied. New modalities of local delivery are being investigated on the possibility of optimizing the beneficial effects of these pharmacological or molecular probes and simoultaneously reducing their potential side-effects. The availability of an effective local delivery modality could have a significant impact in the studies using gene delivery approaches in the prevention of restenosis. More recently we are also studying the possible implication of apoptosis both in the ethiopatogenesis of restenosis and its potential modulation as a novel approach to the prevention of restenosis post PCI or stent implantation. Several experimental in vivo and in vitro models have being developed and in use for these purposes.
Ibanez B, Cimmino G, Benezet-Mazuecos J, Santos-Gallego CG, Pinero A, Prat-Gonzalez S, Speidl WS, Fuster V, Garcia MJ, Sanz J, Badimon JJ. Quantification of serial changes in plaque burden using multi-detector computed tomography in experimental atherosclerosis. Atherosclerosis 2008;.
Ibanez B, Vilahur G, Cimmino G, Speidl WS, Pinero A, Choi BG, Zafar MU, Santos-Gallego CG, Krause B, Badimon L, Fuster V, Badimon JJ. Rapid change in plaque size, composition, and molecular footprint after recombinant apolipoprotein A-IMilano (ETC-216) administration. J Am Coll Cardiol 2008; 51: 1104-1109.
Ibanez B, Prat-Gonzalez S, Speidl WS, Vilahur G, Pinero A, Cimmino G, Garcia MJ, Fuster V, Sanz J, Badimon JJ. Early metoprolol administration during persistent coronary occlusion results in increased myocardial salvage: an analysis of ischemic myocardium at risk using cardiac MRI. Circulation 2007; 115: 2909-2916.
Zafar MU, Vorchheimer DA, Gaztanga J, Velez M, Yadegar D, Moreno PR, Kunitada S, Pagan J, Fuster V, Badimon JJ. Antithrombotic effects of factor Xa inhibition with DU-176b: phase-I study of an oral, direct factor Xa inhibitor using an ex-vivo flow chamber. Thromb Haemost 2007; 98: 883-888.
Ibanez B, Vilahur G, Speidl W. Rapid Change in Plaque Size and Molecular Footprint Follow. JACC 2008; 18(51): 1104-1109.
Cimmino G, Ibanez B, Vilahur G, Speidl W, Fuster V, Badimon L, Badimon J. Up-Regulation of Reverse Cholesterol Transport Key Players and Rescue from Global Inflammation by ApoA-I. J Cell Mol Med 2009; 13: 3226-3235.
Cimmino G, Chen W, Speidl W, Giannarelli C, Ibanez B, Fuster V, Hajjar R, Walsh C, Badimon J. Safe and sustained over-expression of functional ApoA-I/HDL in ApoA-I null mice by muscular AAV8 gene transfer. J Cardiovasc Pharmocol 2009; 54: 405-411.
Zafar M, Ibanez B, Choi B, Vorchheimer D, Pinero A, Jin X, Sharma R, Badimon J. An oral antiplatelet agent with potent antithrombotic properties: comparison of DZ-697b with clopidogrel in a randomised phase I study. Thromb Haemost 2010; 103: 205-212.
Zafar M, Paz-Yepes M, Shimbo D, Vilahur G, Burg M, Chaplin W, Fuster V, Davidson K, Badimon J. Anxiety is a Better Predictor of Platelet Reactivity in Acute Coronary Syndrome Survivors than Depression. European Heart Journal 2010;.
Speidl W, Cimmino G, Ibanez B, Elmariah S, Hutter R, Garcia M, Fuster V, Goldman M, Badimon J. Apolipoprotein A-I Milano Rapidly Reverses Aortic Valve Stenosis and Decreases Leaflet Inflammation in a Hypercholesterolemic Rabbit Model. European Heart Journal 2010;.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Badimon during 2016 and/or 2017. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Other activities: Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.